Completed PHASE2 INTERVENTIONAL 3-arm NCT01890941

A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Sponsor: Kissei Pharmaceutical Co., Ltd.

Interventions KCT-0809 ophthalmic solution Placebo

Updated 5 times since 2017 Last updated: Oct 16, 2015 Primary completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01890941, this PHASE2 trial focuses on Dry Eye Syndromes and remains completed. Sponsored by Kissei Pharmaceutical Co., Ltd., it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo and Other Japanese City, Japan